# Can we Use a Simple Blood Test to Reduce Unnecessary Adverse Effects From Radiotherapy by Timely Identification of Radiotherapy-resistant Rectal Cancers? MeD-Seq Rectal Study

> **NCT06035471** · — · NOT_YET_RECRUITING · sponsor: **Erasmus Medical Center** · enrollment: 75 (estimated)

## Conditions studied

- Pathological Response Rate, Circulating Tumour DNA

## Interventions

- **DIAGNOSTIC_TEST:** MeD-seq

## Key facts

- **NCT ID:** NCT06035471
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-10-01
- **Primary completion:** 2026-06-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2023-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06035471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06035471, "Can we Use a Simple Blood Test to Reduce Unnecessary Adverse Effects From Radiotherapy by Timely Identification of Radiotherapy-resistant Rectal Cancers? MeD-Seq Rectal Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06035471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*